Prevention of cardiovascular disease

Diabetes Care

Volumn 30, Issue 2, 2007, Pages 423-431

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MURAGLITAZAR; NATEGLINIDE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; SPIRONOLACTONE; SULFONYLUREA; TESAGLITAZAR; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; EDEMA; FEEDING BEHAVIOR; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; META ANALYSIS; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; METABOLIC SYNDROME X; NEW YORK CITY; PHYSICAL FITNESS; PREDIABETIC STATE; PREVALENCE; SOCIETIES, SCIENTIFIC;

EID: 33846660734     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-zb02     Document Type: Review

References (30)

1. Kopelman PG: Obesity as a medical problem. Nature 404:635-643, 2000
2. Kant AK, Schatzkin A, Graubard BI, Schairer C: A prospective study of diet quality and mortality in women. JAMA 283:2109-2115, 2000
3. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 343:16-22, 2000
4. Ardern CI, Katzmarzyk PT, Janssen I, Church TS, Blair SN: Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic. Circulation 112:1478-1485, 2005
5. Oguma Y, Shinoda-Tagawa T: Physical activity decreases cardiovascular disease risk in women: review and meta-analysis. Am J Prev Med 26:407-418, 2004
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, the Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
8. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, the Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673-1679, 2006
9. Sarlio-Lahteenkorva S, Rissanen A, Kaprio J: A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults. Int J Obes Relat Metab Disord 24:116-125, 2000
10. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ, the Look AHEAD Research Group: Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24:610-628, 2003
11. Eckel RH, Hernandez TL, Bell ML, Weil KM, Shepard TY, Grunwald GK, Sharp TA, Francis CC, Hill JO: Carbohydrate balance predicts weight and fat gain in adults. Am J Clin Nutr 83:803-808, 2006
12. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453-462, 2003
13. Resnick HE, Foster GL, Bardsley J, Ratner RE: Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29:531-537, 2006
14. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW: Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes: the Troglitazone Study Group. Diabetes Care 21:1462-1469, 1998
15. Chiquette E, Ramirez G, Defronzo R: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104, 2004
16. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, the GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554, 2005
17. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1744-1749, 2003
18. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gem-fibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113:1556-1563, 2006
19. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD, the Rosiglitazone Study 108 Investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947-952, 2002
20. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
21. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 102:21-27, 2000
22. DAIS Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910, 2001
23. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, the FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
24. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, the DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485-493, 2005
25. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, the CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
26. Wald DS, Wald NJ, Morris JK, Law M: Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333:1114-1117, 2006
27. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590, 2005
28. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17:3482-3490, 2006
29. Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO, Li S: Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 1:803-812, 2001
30. Kendall D, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 29:1016-1023, 2006